Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
An Open-label Study to Assess the Efficacy and Safety of Extended TARPEYO® (Delayed-release Budesonide Capsules) Treatment in Adult Patients With Primary IgA Nephropathy Who Have Completed 9 Months of TARPEYO® 16 mg Once Daily Treatment in Real-world Clinical Practice
Calliditas Therapeutics AB
60 participants
Dec 17, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will * take part in this study for about 19 months * Have urine tests done * Have blood samples taken * Have physical examinations done
Eligibility
Inclusion Criteria6
- Diagnosed IgAN with biopsy verification
- Female or male participants ≥18 years of age
- Completion of a single, initial 9 months of treatment with TARPEYO® 16 mg QD at the Baseline visit
- Access to retrospective local laboratory assessment data on UPCR and serum creatinine. Available retrospective data should include at least 1 assessment timepoint within 3 months prior to the first dose of TARPEYO® commercial treatment.
- On stable treatment with renin-angiotensin system (RAS) inhibitor therapy or sparsentan for at least 8 weeks prior to the Baseline visit. A stable dose is defined as a dose within 25% of the dose at Baseline.
- If on current treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitor, the treatment should have been stable for at least 8 weeks prior to the Baseline visit. A stable dose is defined as a dose within 25% of the dose at Baseline.
Exclusion Criteria14
- Participants who have been treated with systemic immunosuppressive medications including glucocorticosteroids (GCS) other than TARPEYO® during the TARPEYO® commercial treatment period. Topical or inhalation products containing GCS or immunosuppressants are allowed.
- Presence of other glomerulopathies (e.g., C3 glomerulopathy, diabetes nephropathy and/or hypertensive nephropathy).
- Presence of nephrotic syndrome (i.e., proteinuria \>3.5 g per day and serum albumin \<3.0 g/dL, with or without edema).
- Presence of medical condition excluding continued TARPEYO® treatment, as assessed by the Investigator.
- On current or planned dialysis.
- Undergone kidney transplant.
- Poorly controlled diabetes mellitus or hypertension, as assessed by the Investigator.
- Participants with known osteoporosis in the medium- or high-risk category according to the 2010 American College of Rheumatology recommendations.
- Any medical or social circumstance making trial participation and/or TARPEYO® treatment unsuitable, as assessed by the Investigator.
- Participants with clinically significant infections that put the participant at risk, at the discretion of the Investigator.
- Participants unwilling or unable to meet the requirements of the protocol.
- Intake of another investigational drug during trial, or during the preceding 9-monthcommercial TARPEYO® treatment period.
- Females who are pregnant, breastfeeding, or plan to become pregnant in the trial period.
- Participants taking potent inhibitors of cytochrome P450 (CYP) 3A4
Interventions
6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.
Locations(38)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06712407